Analysts expect that MEDNAX Inc (NYSE:MD) will post $886.36 million in sales for the current quarter, according to Zacks. Eight analysts have provided estimates for MEDNAX’s earnings, with the highest sales estimate coming in at $894.51 million and the lowest estimate coming in at $876.50 million. MEDNAX posted sales of $830.77 million during the same quarter last year, which would indicate a positive year over year growth rate of 6.7%. The business is scheduled to report its next quarterly earnings report on Tuesday, February 6th.

According to Zacks, analysts expect that MEDNAX will report full year sales of $886.36 million for the current year, with estimates ranging from $3.42 billion to $3.44 billion. For the next financial year, analysts forecast that the business will report sales of $3.66 billion per share, with estimates ranging from $3.59 billion to $3.75 billion. Zacks’ sales calculations are an average based on a survey of research firms that cover MEDNAX.

MEDNAX (NYSE:MD) last posted its earnings results on Wednesday, November 1st. The company reported $0.87 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.87. The business had revenue of $868.95 million for the quarter, compared to analysts’ expectations of $864.78 million. MEDNAX had a net margin of 7.76% and a return on equity of 10.80%. The business’s revenue for the quarter was up 4.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.09 EPS.

MD has been the topic of several recent research reports. KeyCorp upgraded shares of MEDNAX from a “sector weight” rating to an “overweight” rating and set a $51.00 price objective on the stock in a research note on Sunday, September 17th. Jefferies Group reiterated a “hold” rating and issued a $46.00 price objective on shares of MEDNAX in a research note on Tuesday, October 3rd. Zacks Investment Research upgraded shares of MEDNAX from a “sell” rating to a “hold” rating in a research note on Wednesday, October 11th. BMO Capital Markets initiated coverage on shares of MEDNAX in a research note on Monday, October 16th. They issued a “market perform” rating and a $46.00 price objective on the stock. Finally, Robert W. Baird increased their price objective on shares of MEDNAX from $47.00 to $48.00 and gave the stock a “neutral” rating in a research note on Friday, November 3rd. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and three have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $53.82.

In related news, insider John C. Pepia sold 3,000 shares of the stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $51.58, for a total value of $154,740.00. Following the completion of the sale, the insider now directly owns 35,569 shares of the company’s stock, valued at approximately $1,834,649.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Cesar L. Alvarez sold 10,668 shares of the stock in a transaction that occurred on Friday, November 3rd. The stock was sold at an average price of $42.59, for a total transaction of $454,350.12. Following the completion of the sale, the director now directly owns 44,215 shares of the company’s stock, valued at $1,883,116.85. The disclosure for this sale can be found here. Corporate insiders own 2.40% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in MD. Fuller & Thaler Asset Management Inc. purchased a new stake in MEDNAX during the 3rd quarter valued at approximately $103,000. Pacer Advisors Inc. grew its holdings in MEDNAX by 8.1% during the 2nd quarter. Pacer Advisors Inc. now owns 1,940 shares of the company’s stock valued at $117,000 after buying an additional 145 shares in the last quarter. Commonwealth Bank of Australia grew its holdings in MEDNAX by 15.3% during the 2nd quarter. Commonwealth Bank of Australia now owns 2,205 shares of the company’s stock valued at $132,000 after buying an additional 293 shares in the last quarter. Denali Advisors LLC purchased a new stake in MEDNAX during the 3rd quarter valued at approximately $185,000. Finally, Meiji Yasuda Asset Management Co Ltd. grew its holdings in MEDNAX by 45.3% during the 3rd quarter. Meiji Yasuda Asset Management Co Ltd. now owns 5,230 shares of the company’s stock valued at $226,000 after buying an additional 1,630 shares in the last quarter. 98.43% of the stock is owned by institutional investors and hedge funds.

MEDNAX (NYSE MD) traded up $0.05 on Friday, reaching $54.61. 1,249,500 shares of the company’s stock traded hands, compared to its average volume of 902,933. The company has a quick ratio of 1.37, a current ratio of 1.37 and a debt-to-equity ratio of 0.62. The company has a market cap of $5,109.83, a PE ratio of 19.30, a P/E/G ratio of 1.64 and a beta of 0.39. MEDNAX has a 1-year low of $40.56 and a 1-year high of $72.13.

TRADEMARK VIOLATION NOTICE: This piece of content was published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/01/05/886-36-million-in-sales-expected-for-mednax-inc-md-this-quarter-2.html.

About MEDNAX

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Get a free copy of the Zacks research report on MEDNAX (MD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.